MDACC Study No:2010-0736 ( NCT No: NCT01272245)
Title:A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Principal Investigator:Hagop Kantarjian
Treatment Agent:Cytarabine; Omacetaxine Mepesuccinate
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if omacetaxine given with
cytarabine can help to control the disease in patients with AML or high-risk
MDS. The safety of the study drugs will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cytarabine
Omacetaxine Mepesuccinate
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Cephalon, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults